What is the definition of triple hit multiple myeloma (MM)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 7, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Research

Triple hit multiple myeloma is defined as the presence of three or more high-risk cytogenetic abnormalities, including del(17p), t(4;14), t(14;16), t(14;20), gain 1q, del 1p, or p53 mutation, and is associated with poorer outcomes and shorter survival compared to standard-risk myeloma. The diagnosis of multiple myeloma requires ≥10% clonal bone marrow plasma cells or a biopsy-proven plasmacytoma plus evidence of one or more multiple myeloma defining events (MDE) 1. The presence of high-risk cytogenetic abnormalities is a key factor in determining the prognosis and treatment of multiple myeloma.

Key Characteristics of Triple Hit Multiple Myeloma

  • Presence of three or more high-risk cytogenetic abnormalities
  • Associated with poorer outcomes and shorter survival compared to standard-risk myeloma
  • Requires more intensive treatment approaches, including proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies
  • High-dose chemotherapy followed by autologous stem cell transplantation is usually recommended for eligible patients
  • Maintenance therapy is crucial to extend remission duration

Treatment Approaches for Triple Hit Multiple Myeloma

  • Induction therapy with bortezomib, lenalidomide, and dexamethasone (VRd) or daratumumab, bortezomib, lenalidomide, and dexamethasone (Dara-VRd) 2
  • High-dose chemotherapy followed by autologous stem cell transplantation for eligible patients
  • Maintenance therapy with lenalidomide or bortezomib plus lenalidomide for high-risk patients
  • Consideration of novel agents, such as CAR-T cell therapy and bispecific antibodies, for relapsed or refractory disease 1

Importance of Early Identification and Risk Stratification

  • Early identification of high-risk cytogenetic abnormalities through cytogenetic testing is essential for appropriate risk stratification and treatment planning
  • Risk assessment is a crucial determinant of treatment and outcomes in multiple myeloma 3
  • Patients with triple hit multiple myeloma require close monitoring and aggressive treatment approaches to improve outcomes.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.